Claims for Patent: 9,839,617

Summary for Patent: 9,839,617

Title:	Nanoencapsulation of hydrophilic active compounds
Abstract:	Provided is a nanoparticle including a water-soluble protein, a glucan and a hydrophilic active agent, the glucan being at least partially cross-linked by a metaphosphate.
Inventor(s):	Benita; Simon (Tel Aviv, IL), Nassar; Taher (Kfar Tur\'an, IL), Kochavi-Soudry; Liat (Shoham, IL)
Assignee:	Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (Jerusalem, IL)
Application Number:	15/114,212
Patent Claims:	1. A nanoparticle comprising a matrix of albumin and a glucan, the matrix encapsulating a hydrophilic active agent, the glucan being at least partially cross-linked by sodium trimetaphosphate (STMP), wherein the albumin, at least one glucan and at least one hydrophilic active agent are uniformly distributed. 2. The nanoparticle of claim 1, wherein said albumin is selected from human serum albumin (HSA) and bovine serum albumin (BSA). 3. The nanoparticle of claim 1, wherein the glucan is an .alpha.-glucan. 4. The nanoparticle of claim 3, wherein said a-glucan is selected from dextran, glycogen, pullulan, starch, lichenin, mannan, galactomannan, arabinoxylan, and galacton. 5. The nanoparticle of claim 1, wherein said glucan has a molecular weight of between about 5 KDa and 2,000 KDa. 6. The nanoparticle of claim 1, wherein said hydrophilic active agent comprises --NH.sub.2 moieties. 7. The nanoparticle of claim 1, wherein said hydrophilic active agent is selected from a vitamin, a protein, an anti-oxidant, a peptide, a polypeptide, a carbohydrate, a hormone, an antibody, a monoclonal antibody, a vaccine, a prophylactic agent, a diagnostic agent, a contrasting agent, a nucleic acid, a nutraceutical agent, a small molecule of a molecular weight of less than about 1,000 Da, an electrolyte, a drug, an immunological agent, and combinations thereof. 8. The nanoparticle of claim 7, wherein said hydrophilic active agent is selected from the group consisting of insulin, exenatide, growth hormone, octreotide acetate, lanreotide acetate, goserelin acetate, copaxone, etanercept, and monoclonal antibodies. 9. The nanoparticle of claim 7, wherein said hydrophilic active agent is selected from insulin and exenatide. 10. The nanoparticle of claim 1, having a diameter of at most 500 nm. 11. The nanoparticle of claim 10, having a diameter between about 50 nm and 250 nm. 12. The nanoparticle of claim 1, being a nanosphere or a nanocapsule. 13. A carrier comprising a hydrophobic polymer and a plurality of nanoparticles as claimed in claim 1, the plurality of nanoparticles being (i) encapsulated by said hydrophobic polymer or (ii) embedded in a matrix formed of said hydrophobic polymer. 14. The carrier of claim 13, wherein said hydrophobic polymer is selected from poly(lactic glycolic) acid (PLGA), polymethyl-methacrylate (PMMA), hydroxypropyl methylcellulose (HPMC), poly(lactic acid) (PLA), poly(lacto-co-glycolide) (PLG), poly(lactide), polyglycolic acid (PGA), and poly(hydroxybutyrate). 15. The carrier of claim 13, wherein the nanoparticles are encapsulated in microcapsules or embedded in microparticles, the microcapsules or microparticles having a diameter of between 1 and 30 microns. 16. A pharmaceutical composition comprising the nanoparticle of claim 1 and further comprising a carrier. 17. The pharmaceutical composition of claim 16, being adapted for topical, oral, inhalation, nasal, transdermal, ocular or parenteral administration of said hydrophilic active agent. 18. The delivery system of claim 13, further encapsulated within a biodegradable capsule, wherein said biodegradable capsule is optionally in the form of an entero-coated capsule. 19. A process for the preparation of a nanoparticle comprising albumin, a glucan and a hydrophilic active agent, the glucan being at least partially cross-linked by sodium trimetaphosphate (STMP), the process comprising: mixing a first aqueous solution comprising albumin and said glucan with a second aqueous solution comprising said hydrophilic active agent to form a mixture; delivering an organic solvent into said mixture; and adding sodium trimetaphosphate to said mixture to thereby at least partially cross-link said glucan for obtaining said nanoparticle.

Details for Patent 9,839,617

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Immunex Corporation	ENBREL	etanercept	For Injection	103795	11/02/1998		2039-02-26
Immunex Corporation	ENBREL	etanercept	For Injection	103795	05/27/1999		2039-02-26
Immunex Corporation	ENBREL	etanercept	Injection	103795	09/27/2004		2039-02-26